Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.
Orgenesis Inc. reports developments in cell and gene therapies, decentralized cell processing, and regenerative medicine. Company news has centered on its CGT platform, GMP-validated production capabilities for CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomes, as well as ORG-101, a CD19 CAR-T therapy studied in acute lymphoblastic leukemia.
Recurring updates also cover portfolio expansion through regenerative medicine assets for spinal cord injury, partnerships with hospitals, research institutions, and healthcare groups, and financing arrangements used to support platform rollout. Corporate news includes trading-market changes, reverse stock split actions, listing-compliance matters, and other capital-structure developments affecting ORGS common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.